Peptide comparisons on TikTok: what the science actually supports

What did @dr.tommymartin actually say?

The creator pushed back on a viral TikTok trend comparing alcohol-related deaths to peptide deaths, arguing the comparison is emotionally compelling but logically hollow. He said the alcohol figure refers to "population level deaths associated with alcohol use" across millions of people over decades, while peptides occupy a fundamentally different regulatory and evidentiary category. His core point: the absence of a peptide death count is not evidence of safety. It is evidence of a data gap.

He was responding to a specific rhetorical move circulating online, where creators appear to use alcohol mortality statistics to imply that unregulated peptides are comparatively harmless. He rejected that framing directly, arguing both things can simultaneously be true: alcohol is genuinely dangerous, and unregulated peptides sold as "research chemicals" deserve serious skepticism before anyone injects them.

Does the science back this up?

Largely, yes. The alcohol death statistics he references are well-documented. The CDC and WHO have both published consistent data showing alcohol causes approximately 95,000 deaths annually in the U.S. alone when cirrhosis, cancer, accidents, and fetal alcohol effects are combined. The 178,000 figure he cites likely reflects more recent or broader global-adjacent U.S. estimates, which have trended upward post-pandemic.

On peptides, he is correct that the human safety literature is thin. A 2023 review by Bray and colleagues in Frontiers in Pharmacology noted that most peptide therapeutics in the research pipeline, including BPC-157 and TB-500, have primarily rodent-model data, with very limited controlled human trials. The FDA has not approved these compounds for clinical use, and the compounding pharmacy pathway for some peptides has been subject to enforcement actions. Critically, third-party testing of products sold as peptides online has found contamination, mislabeling, and incorrect concentrations in a meaningful percentage of samples, per analytical chemistry analyses published in Drug Testing and Analysis (Thevis et al., 2019).

What did they get wrong (or right)?

He got the core argument right, and credit is warranted for calling out a bad rhetorical comparison rather than amplifying it. However, there is a nuance worth flagging. He frames all peptides being sold online as uniformly uncharacterized, which is not fully accurate. Some peptides, like sermorelin and certain GLP-1 analogs, have substantial human clinical data and regulatory history, even if the specific products sold online are unregulated versions of those compounds.

His statement that "no dose of alcohol is safe" reflects mainstream public health consensus, including the 2023 updated guidance from the Canadian Centre on Substance Use and Addiction and a 2018 Lancet meta-analysis (GBD 2016 Alcohol Collaborators) that found no safe level of alcohol for overall health. That position is scientifically defensible, if contested in some corners of the epidemiology literature around light drinking and cardiovascular outcomes.

Where he could have been more precise: the regulatory status of peptides varies considerably. Lumping BPC-157 and GHK-Cu together with something like sermorelin in a single "unregulated research chemical" bucket slightly overstates the homogeneity of the category.

What should you actually know?

The absence of a body count is not the same as a safety record. Peptides sold online as research chemicals are not subject to FDA manufacturing standards, which means you genuinely do not know what is in the vial. This is not a hypothetical risk. Independent lab analyses have found bacterial endotoxins, incorrect peptide sequences, and unlisted additives in commercially available research peptide products.

The comparison this video debunks is a logical fallacy called "relative harm deflection," where the danger of one substance is minimized by pointing to the documented harms of a worse or more widely used substance. The fact that alcohol kills tens of thousands of people annually tells you nothing about whether an unregulated injectable compound manufactured without GMP oversight is safe for human use.

If you are considering peptide therapy for any purpose, the evidence base for most compounds being discussed on social media is preliminary at best. Working with a licensed clinician through a regulated platform, where sourcing, dosing, and monitoring are part of the protocol, is a materially different situation than purchasing unlabeled compounds from a research chemical vendor.